安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label . . . - PubMed
MyPathway evaluates the activity of targeted therapies in non-indicated tumour types with potentially predictive molecular alterations We aimed to assess the activity of pertuzumab and trastuzumab in patients with HER2-amplified metastatic colorectal cancer Methods: MyPathway is an ongoing, phase 2a, multiple basket study
- Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real . . .
Combination therapy of pertuzumab plus trastuzumab (PER-HER) showed promising results for patients with treatment-refractory HER2-Amp mCRC in the single-arm, phase IIa MyPathway multibasket study and is listed in the National Comprehensive Cancer 13
- Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP . . . - ScienceDirect
Trastuzumab pertuzumab treatment confers clinical benefit in almost half of HER2+ mCRC patients Treatment with trastuzumab plus pertuzumab was well tolerated Whole genome sequencing data may reveal potential resistance mechanisms to trastuzumab pertuzumab treatment
- Pertuzumab + trastuzumab for HER2-amplified overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. - ASCO
We present updated data for an expanded cohort of patients with HER2-amplified overexpressed mCRC receiving HER2-targeted therapy with pertuzumab + trastuzumab Methods: MyPathway (NCT02091141) is a multicenter, open-label, phase IIA study
- Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a . . .
In this current subset analysis of data from MyPathway, we assess the efficacy of HER2-amplified mCRC treatment with pertuzumab + trastuzumab, free of systemic chemotherapy This dual HER2-targeted regimen, in combination with a taxane, comprises a first-line standard of care in patients with HER2-positive metastatic breast cancer
- Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2 -Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway . . . - ResearchGate
PURPOSE We compared overall survival (OS) in patients with human epidermal growth factor receptor 2 ( HER2)–amplified, treatment-refractory metastatic colorectal cancer (mCRC) receiving
- Pertuzumab Plus Trastuzumab for HER2-Ampli ColorectalCancer:ComparisonoftheMyPathway Trial With a Real-World External Control Arm - ASCO Publications
Combination therapy of pertuzumabplus trastuzumab (PER-HER) showed promising results for patients with treatment-refractory HER2-Amp mCRC in the single-arm, phase IIa MyPathway multibasket study and is listed in the National Comprehensive Cancer
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase . . .
Results from the MyPathway trial (reported herein) and the HERACLES trial support the use of dual HER2-targeted therapy, trastuzumab plus pertuzumab or lapatinib, in patients with HER2-positive, KRAS wild-type metastatic colorectal cancer
|
|
|